See original paper on page 1326
In old age the flesh becomes tough, that is because the collagen increases in the connective tissue – the lime, you know, the most important constituent of the bones and cartilage. (Thomas Mann, ‘The Magic Mountain’, 1924)
In this issue of the Journal of Hypertension, Qian et al. have reported the results of a study showing that first morning voiding urine sample may be a valid low-burden, low-cost alternative for the estimation of mean population salt intakes [1]. They conclude that the International Study of Sodium, Potassium, and Blood Pressure (INTERSALT) formula may exhibit good performance in terms of mean 24-h sodium estimation for the hypertensive population living in northeast China. According to the World Health Organization, the systematic intake of excess salt in comparison with the physiological norm leads to an increase in blood pressure and, as a consequence, to a variety of heart and kidney diseases, stomach cancer, and osteoporosis [2]. The physiological norm for one person is 5 g of salt per day. In Europe and the United States, however, the average person consumes about 10 g [3]. The link between dietary sodium intake, hypertension, and progressive loss of cardiovascular and renal functions is strong and has been demonstrated in many epidemiological studies in humans [2–4]. In the prehistorical age (<10 000 years BC) our ancestors consumed <0.5 g/day, NaCl intake increased significantly due to food preservation with salt and reached 18 g/day. Following the invention of refrigerators, salt consumption dropped to 10 g/day but remained significantly greater than the amount recommended by the dietitians, NaCl intake (5–6 g/day) [4].
Remarkably, the results of Qian et al. demonstrate that INSERSALT, a program that previously used 24-h urine collection and blood pressure measurements in 10 079 adults from 32 countries, exhibited a good fit in estimating 24-h urinary sodium excretion [1]. INTERSALT has shown a direct relationship between salt intake as measured by daily urine sodium and blood pressure. This finding has been supported by numerous other large epidemiological studies [2]. Importantly, INTERSALT also found an association between salt intake and an increase in blood pressure with age, suggesting that, lowering salt levels may slow the increase in blood pressure with age [5]. In European countries, programs have been launched to explain the harmful consequences of salt abuse, in Finland, for example, it was possible to reduce salt intake by one-third, due to which the death rate from strokes and heart attacks decreased by 80% [6].
If doubts exist whether or not excessive salt intake harms, the arguments that moderate salt restriction does harm are weak. There are many conditions of different etiologies and pathogeneses which usually result in, but are not limited to the increases in blood pressure. However, very moderate blood pressure increases may be associated with severe vascular remodeling leading to end-organ damage [7]. Moreover, increased NaCl intake may damage the cardiovascular system without elevations of the blood pressure, that is, cause fibrosis [8]. With the results of Qian, we will get a confirmation in larger population groups of various ethnic backgrounds, and it will be possible to use spot urinary sampling for 24-h urinary sodium for prediction in thousands of aged hypertensive patients, patients with fibrosis of different origin, and ones with chronic kidney disease.
Many factors are involved in the genesis of fibrosis including cardiotonic steroids, like bufadienolides originally found in animals like toad Bufo marinus [9]. Cardiotonic steroids inhibit the Na/K-ATPase and regulate the monovalent ions balance and cell homeostasis. Moreover, by binding to the Na/K-ATPase, cardiotonic steroids can affect cell growth and differentiation, apoptosis and proliferation, glucose metabolism, and control of central nervous functions [9]. An important effect of cardiotonic steroids is their ability to function as pro-fibrotic factors, that is to start intracellular signaling cascades leading to a loss of elasticity and vascular fibrosis [10]. One of the mechanisms underlying the pro-fibrotic effect of marinobufagenin is the altered activity of Fli1, a nuclear transcription factor and a negative regulator of collagen-1 synthesis [10]. The inhibition of Fli1, a member of the erythroblast transformation specific (ETS) family, is critical for marinobufagenin-induced fibrosis [10].
Fli1 acts as a negative regulator of collagen-1 synthesis and it competes with another transcription factor, ETS-1, to maintain a balance between stimulation and repression of the collagen-1 gene [11,12]. The Na/K-ATPase/Src/epidermal growth factor receptor complex begins a signal cascade, which activates phospholipase C resulting in the phosphorylation of protein kinase C (PKC)δ and its translocation to the nucleus. In the nucleus, phosphorylated PKCδ phosphorylates Fli1, which withdraws the Fli1-induced inhibition of the collagen-1 promoter and increases procollagen expression and collagen production [10]. Pro-fibrotic effects initiated by marinobufagenin may be small mothers against decapentaplegic- and transforming growth factor beta-1-dependent and underlie vascular fibrosis in salt-induced normotensive and hypertensive rats [10,13]. Interestingly, the same mechanism of synthesis of collagen-1, Fli1-dependent fibrosis, emerges in several disorders associated with enhanced consumption of salt and includes age-dependent hypertension [14] and hypertension in the younger population [15], chronic kidney disease [16]. Excessive dietary NaCl may also alter vascular structure and function via cardiotonic steroid mechanisms in the setting of age-associated reductions in renal blood flow and in the ability to excrete sodium [17]. In another study, male marinobufagenin responders versus nonresponders had markedly enhanced salt sensitivity [18]. In men, marinobufagenin increases with 24-h blood pressure, and similar to Dahl salt-sensitive rats, 4 weeks of high-salt induced marinobufagenin response is accompanied by marked salt sensitivity [18]. These findings indicated the causative link between salt intake, vascular stiffness, and marinobufagenin, an endogenous natriuretic hormone and Na/K-ATPase inhibitor.
Interestingly, when Yanomamo people were studied their blood pressure was around 100/64 mmHg and sodium excretion was 1 mEq Na+ 24 h versus 104 mEq Na+ in a group of control individuals [19]. A question, therefore, is becoming apparent, do Yanomamo have fibrosis, do their arteries become stiff and what are their levels of cardiotonic steroids? The study by Qian et al. offers convincing proof of the link between salt intake and blood pressure, we have to connect the story to fibrosis.
Acknowledgements
A.Y.B. is supported by a Russian Scientific Foundation Grant (No. 18-15-00222).
Conflicts of interest
There are no conflicts of interest.
References
| # | Year | Authors | Title |
|---|---|---|---|
| 1 | 2021 | Qian N, Jiang Y, Wang Y, Yan P, Yao F, Sun M, et al | Validity of five formulas in estimating 24-h urinary sodium via 3 spot urine sampling in hypertensive patients living in Northeast China. Hypertens 2021; 39:1326–1332. |
| 2 | 2020 | He FJ, Tan M, Ma Y, MacGregor GA | Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75:632–647. [CrossRef] |
| 3 | 1988 | INTERSALT Cooperative Research Group | INTERSALT: an international study of electrolyte excretion and blood pressure: results for 24 h urinary sodium and potassium excretion. BMJ 1988; 297:319–328. [CrossRef] [PubMed] |
| 4 | 1998 | MacGregor G, De Wardener H | Salt, diet and health. Cambridge, UK: Cambridge University Press; 1998 . |
| 5 | 2004 | Gates PE, Tanaka H, Hiatt WR, Seals DR | Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004; 44:35–41. [CrossRef] [PubMed] |
| 6 | 2019 | Campbell NRC, He FJ, Tan M, Cappuccio FP, Neal B, Woodward M, et al | The International Consortium for Quality Research on Dietary Sodium/Salt (TRUE) position statement on the use of 24-h, spot, and short duration (<24 h) timed urine collections to assess dietary sodium intake. J Clin Hypertens 2019; 21:700–709. [CrossRef] [PubMed] |
| 7 | 2003 | Lakatta EG | Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. cellular and molecular clues to heart and arterial aging. Circulation 2003; 107 (Pt 3):490–497. [CrossRef] [PubMed] |
| 8 | 1990 | Tobian L, Hanlon S | High sodium chloride diets injure arteries and raise mortality without changing blood pressure. Hypertension 1990; 15:900–903. [CrossRef] [PubMed] |
| 9 | 2009 | Bagrov AY, Shapiro JI, Fedorova OV | Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 2009; 61:9–38. [CrossRef] [PubMed] |
| 10 | 2006 | Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, et al | Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006; 47:488–495. [CrossRef] [PubMed] |
| 11 | 2000 | Blair DG, Athanasiou M | Ets and retroviruses—transduction and activation of members of the Ets oncogene family in viral oncogenesis. Oncogene 2000; 19:6472–6481. [CrossRef] [PubMed] |
| 12 | 2003 | Oikawa T, Yamada T | Molecular biology of the Ets family of transcription factors. Gene 2003; 303:11–34. [CrossRef] [PubMed] |
| 13 | 2018 | Grigorova YN, Wei W, Petrashevskaya N, Zernetkina Z, Juhasz O, Fenner R, et al | Dietary sodium restriction reduces arterial stiffness, vascular TGF-b-dependent fibrosis and marinobufagenin in young normotensive rats. Int J Mol Sci 2018; 19:3168. [CrossRef] |
| 14 | 2008 | Anderson DE, Fedorova OV, Morrell CH, Longo DL, Kashkin VA, Metzler JD, et al | Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am J Physiol Regul Integr Comp Physiol 2008; 294:R1248–R1254. [CrossRef] [PubMed] |
| 15 | 2018 | Strauss M, Smith W, Wei W, Fedorova OV, Schutte AE | Marinobufagenin is related to elevated central and 24-h systolic blood pressures in young black women: the African-PREDICT Study. Hypertens Res 2018; 41:183–192. [CrossRef] [PubMed] |
| 16 | 2011 | Kolmakova EV, Haller ST, Kennedy DJ, Isachkina AN, Budny GV, Frolova EV, et al | Endogenous cardiotonic steroids in chronic renal failure. Nephrol Dial Transplant 2011; 26:2912–2919. [CrossRef] [PubMed] |
| 17 | 2013 | Jablonski KL, Fedorova OV, Racine ML, Geolfos CJ, Gates PE, Chonchol M, et al | Dietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness. Clin J Am Soc Nephrol 2013; 8:1952–1959. [CrossRef] [PubMed] |
| 18 | 2015 | Fedorova OV, Lakatta EG, Bagrov AY, Melander O | Plasma level of the endogenous sodium pump ligand marinobufagenin is related to the salt-sensitivity in men. J Hypertens 2015; 33:534–541; discussion 541. [CrossRef] [PubMed] |
| 19 | 1975 | Oliver WJ, Cohen EL, Neel JV | Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a ‘no-salt’ culture. Circulation 1975; 52:146–151. [CrossRef] [PubMed] |